

Seeking Genetically-Based Early Discovery Research in Nephrology

BioMarin Pharmaceutical Inc. is a world leader in developing and commercialising **first- or best-in-class therapies for rare genetic diseases**. BioMarin Pharmaceutical Inc. is looking for early discovery research that involve **targets with strong genetic evidence in the area of kidney disease**, with a focus on Autosomal Dominant Polycystic Kidney Disease (ADPKD) and Alport Syndrome.



Approaches of Interest

- Therapeutic approaches to treat **ADPKD, X-linked Alport Syndrome, or all subtypes of Alport Syndrome** treated with the same therapeutic approach
- Unique therapeutic modalities are encouraged
- **Novel approaches for targeted delivery to the kidney**, including adeno-associated virus (AAV) capsids, small molecules, oligonucleotides and drug conjugates for podocyte or distal tubule/collecting duct cell delivery
- **Effective or novel routes of administration to podocytes or distal tubule/collecting duct cells** for the following modalities: AAV, oligonucleotides, small molecules, proteins, and lipid nanoparticles

Developmental Stages of Interest

- Opportunities at basic research phase to Phase I clinical trial are within scope
- Opportunities with *in vivo* validation are of highest interest, although opportunities with *in vitro* validation will still be considered

Submission Information

Submission of one page, 200-300 word briefs are encouraged, along with any optional supplementary information e.g. relevant publications and patents. In submitting to this campaign, you confirm that your submission contains only non-confidential information.

Opportunity for Collaboration

BioMarin Pharmaceutical Inc. is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, and research collaborations. BioMarin Pharmaceutical Inc. is looking to establish long-standing partnerships in the field of nephrology.

Opportunities sought

-  Spinout companies
-  Research projects
-  Centres of excellence
-  Academics and expertise
-  Technologies

Submissions

Please submit relevant, non-confidential opportunities online via: discover.in-part.com

Deadline: **15th November 2021 - 11:59 pm GMT**

Have any questions?

Contact our team at discover@in-part.co.uk

BioMarin Pharmaceutical take pride in going where the science leads them, pioneering breakthrough treatments for debilitating and life-threatening conditions where they can significantly improve upon the current standard of care.